Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis

Cell Reports

Volumn 1, Issue 4, 2012, Pages 325-333

  Lin, Chen Ju ^a   Nasr, Zeina ^a   Premsrirut, Prem K ^c   Porco, John A ^d   Hippo, Yoshitaka ^e   Lowe, Scott W ^a,f,g   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Lustgarten Pancreatic Cancer Research Laboratory   (United States)

^d Boston University   (United States)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4F; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CARCINOGENESIS; CELL REGENERATION; COMPLEX FORMATION; IN VIVO STUDY; LYMPHOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA INTERFERENCE;

EUKARYOTA;

EID: 84861171712     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.02.010     Document Type: Article

References (46)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Balvay L., Lopez Lastra M., Sargueil B., Darlix J.L., Ohlmann T. Translational control of retroviruses. Nat. Rev. Microbiol. 2007, 5:128-140.
3. Beard C., Hochedlinger K., Plath K., Wutz A., Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 2006, 44:23-28.
4. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
5. Bordeleau M.E., Robert F., Gerard B., Lindqvist L., Chen S.M., Wendel H.G., Brem B., Greger H., Lowe S.W., Porco J.A., Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 2008, 118:2651-2660.
6. Cencic R., Carrier M., Galicia-Vázquez G., Bordeleau M.E., Sukarieh R., Bourdeau A., Brem B., Teodoro J.G., Greger H., Tremblay M.L., et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009, 4:e5223.
7. Dever T.E. Gene-specific regulation by general translation factors. Cell 2002, 108:545-556.
8. Duncan R., Milburn S.C., Hershey J.W. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J. Biol. Chem. 1987, 262:380-388.
9. Graff J.R., Konicek B.W., Vincent T.M., Lynch R.L., Monteith D., Weir S.N., Schwier P., Capen A., Goode R.L., Dowless M.S., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 2007, 117:2638-2648.
10. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., Cleveland J.L., Tansey W.P., Lowe S.W. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
11. Hochedlinger K., Yamada Y., Beard C., Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005, 121:465-477.
12. Ilic N., Utermark T., Widlund H.R., Roberts T.M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. USA 2011, 108:E699-E708.
13. Jacobsen K.A., Prasad V.S., Sidman C.L., Osmond D.G. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice. Blood 1994, 84:2784-2794.
14. Jones R.M., Branda J., Johnston K.A., Polymenis M., Gadd M., Rustgi A., Callanan L., Schmidt E.V. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol. Cell. Biol. 1996, 16:4754-4764.
15. Kelly P.N., Puthalakath H., Adams J.M., Strasser A. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 2007, 109:4907-4913.
16. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
17. Koromilas A.E., Lazaris-Karatzas A., Sonenberg N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 1992, 11:4153-4158.
18. Langdon W.Y., Harris A.W., Cory S., Adams J.M. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986, 47:11-18.
19. Larsson O., Li S., Issaenko O.A., Avdulov S., Peterson M., Smith K., Bitterman P.B., Polunovsky V.A. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007, 67:6814-6824.
20. Li S., Takasu T., Perlman D.M., Peterson M.S., Burrichter D., Avdulov S., Bitterman P.B., Polunovsky V.A. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J. Biol. Chem. 2003, 278:3015-3022.
21. Lin C.J., Cencic R., Mills J.R., Robert F., Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 2008, 68:5326-5334.
22. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995, 23:1686-1690.
23. Lucas D.M., Edwards R.B., Lozanski G., West D.A., Shin J.D., Vargo M.A., Davis M.E., Rozewski D.M., Johnson A.J., Su B.N., et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009, 113:4656-4666.
24. Mamane Y., Petroulakis E., Martineau Y., Sato T.A., Larsson O., Rajasekhar V.K., Sonenberg N. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007, 2:e242.
25. McJunkin K., Mazurek A., Premsrirut P.K., Zuber J., Dow L.E., Simon J., Stillman B., Lowe S.W. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc. Natl. Acad. Sci. USA 2011, 108:7113-7118.
26. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108:16669-16674.
27. Mills J.R., Hippo Y., Robert F., Chen S.M., Malina A., Lin C.J., Trojahn U., Wendel H.G., Charest A., Bronson R.T., et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA 2008, 105:10853-10858.
28. Miskimins W.K., Wang G., Hawkinson M., Miskimins R. Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol. Cell. Biol. 2001, 21:4960-4967.
29. Nilsson J.A., Keller U.B., Baudino T.A., Yang C., Norton S., Old J.A., Nilsson L.M., Neale G., Kramer D.L., Porter C.W., Cleveland J.L. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005, 7:433-444.
30. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
31. Paddison P.J., Caudy A.A., Sachidanandam R., Hannon G.J. Short hairpin activated gene silencing in mammalian cells. Methods Mol. Biol. 2004, 265:85-100.
32. Podsypanina K., Politi K., Beverly L.J., Varmus H.E. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc. Natl. Acad. Sci. USA 2008, 105:5242-5247.
33. Premsrirut P.K., Dow L.E., Kim S.Y., Camiolo M., Malone C.D., Miething C., Scuoppo C., Zuber J., Dickins R.A., Kogan S.C., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
34. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 2003, 12:889-901.
35. Rosenwald I.B., Lazaris-Karatzas A., Sonenberg N., Schmidt E.V. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol. Cell. Biol. 1993, 13:7358-7363.
36. Rousseau D., Kaspar R., Rosenwald I., Gehrke L., Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. USA 1996, 93:1065-1070.
37. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 2004, 10:484-486.
38. Saradhi U.V., Gupta S.V., Chiu M., Wang J., Ling Y., Liu Z., Newman D.J., Covey J.M., Kinghorn A.D., Marcucci G., et al. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J. 2011, 13:347-356.
39. Schmitt C.A., Lowe S.W. Apoptosis and chemoresistance in transgenic cancer models. J. Mol. Med. 2002, 80:137-146.
40. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
41. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331-333.
42. Tsumuraya T., Ishikawa C., Machijima Y., Nakachi S., Senba M., Tanaka J., Mori N. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 2011, 81:713-722.
43. van Riggelen J., Yetil A., Felsher D.W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 2010, 10:301-309.
44. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
45. Wendel H.G., Silva R.L., Malina A., Mills J.R., Zhu H., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Teruya-Feldstein J., Pelletier J., Lowe S.W. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007, 21:3232-3237.
46. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.